StreetAlpha
13F holdings · Q3 2026

ARCH Venture Management

Chicago, IL · files as ARCH Venture Management, LLC
Know the moment ARCH Venture Management filesYou follow ARCH Venture Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1274403

ARCH Venture Management reported 17 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KARD (13.8%), PBLS (12.8%) and VIR (8.8%). Compared with Q2 2026, the fund opened new positions in KARD, SANA and SRRK and sold out of TXG and GOSS.

Latest filing: what ARCH Venture Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
7 new0 added0 trimmed2 sold outBought about $617M · sold about $9.7M
New 7
See all 7 →
Added 0

None

Trimmed 0

None

Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.6B+46.6% vs last quarter
Stocks held177 new · 2 sold out
Top 5 weight51.5%fairly concentrated
Turnover39%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KARD
Kardigan Inc
$222M13.8%15MNew position1 of 8
2
PBLS
Parabilis Medicines Inc Com
$207M12.8%6.4MNo change2 of 8
3
VIR
Vir Biotechnology Inc
$142M8.8%12.7MNo change6 of 8
4
SANA
Sana Biotechnology Inc
$134M8.3%45.9MNew position1 of 8
5
SPTX
Seaport Therapeutics Inc
$127M7.9%6.3MNo change2 of 8
6
RAPP
Rapport Therapeutics Inc
$125M7.8%3.7MNo change8 of 8
7
SRRK
Scholar Rock Hldg Corp
$113M7.0%2.3MNew position1 of 8
8
MAZE
Maze Therapeutics Inc
$112M6.9%4.1MNo change7 of 8
9
BEAM
Beam Therapeutics Inc
$111M6.9%4.5MNo change8 of 8
10
ERAS
Erasca Inc
$104M6.4%7.1MNo change8 of 8
🔒 7 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TXG
10X Genomics Inc
$8.4M218K
GOSS
Gossamer Bio Inc
$1.3M8.1M

Reported value

last 8 quarters
$230MQ4 '24
$206MQ1 '25
$299MQ2 '25
$492MQ3 '25
$652MQ4 '25
$677MQ1 '26
$1.1BQ2 '26
$1.6BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

ARCH Venture Management 13F FAQ

What does ARCH Venture Management own?

ARCH Venture Management reported 17 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KARD (13.8%), PBLS (12.8%) and VIR (8.8%). The table above lists every position in the filing (the top 10 without an account).

What did ARCH Venture Management buy and sell in Q3 2026?

Compared with Q2 2026: 7 new positions, 0 added to, 0 trimmed and 2 sold out. New positions include KARD, SANA and SRRK. It sold all of TXG and GOSS.

When will ARCH Venture Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is ARCH Venture Management's portfolio worth?

The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.